220 related articles for article (PubMed ID: 28604122)
1. Blood-stage malaria vaccines: post-genome strategies for the identification of novel vaccine candidates.
Ntege EH; Takashima E; Morita M; Nagaoka H; Ishino T; Tsuboi T
Expert Rev Vaccines; 2017 Aug; 16(8):769-779. PubMed ID: 28604122
[TBL] [Abstract][Full Text] [Related]
2. Vaccine candidates for malaria: what's new?
Takashima E; Morita M; Tsuboi T
Expert Rev Vaccines; 2016; 15(1):1-3. PubMed ID: 26559316
[TBL] [Abstract][Full Text] [Related]
3. Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda.
Kanoi BN; Takashima E; Morita M; White MT; Palacpac NM; Ntege EH; Balikagala B; Yeka A; Egwang TG; Horii T; Tsuboi T
Vaccine; 2017 Feb; 35(6):873-881. PubMed ID: 28089547
[TBL] [Abstract][Full Text] [Related]
4. Malaria transmission-blocking vaccines: wheat germ cell-free technology can accelerate vaccine development.
Miura K; Tachibana M; Takashima E; Morita M; Kanoi BN; Nagaoka H; Baba M; Torii M; Ishino T; Tsuboi T
Expert Rev Vaccines; 2019 Oct; 18(10):1017-1027. PubMed ID: 31566026
[No Abstract] [Full Text] [Related]
5. Vaccine candidate discovery for the next generation of malaria vaccines.
Tuju J; Kamuyu G; Murungi LM; Osier FHA
Immunology; 2017 Oct; 152(2):195-206. PubMed ID: 28646586
[TBL] [Abstract][Full Text] [Related]
6. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
[TBL] [Abstract][Full Text] [Related]
7. Application of wheat germ cell-free protein expression system for novel malaria vaccine candidate discovery.
Arumugam TU; Ito D; Takashima E; Tachibana M; Ishino T; Torii M; Tsuboi T
Expert Rev Vaccines; 2014 Jan; 13(1):75-85. PubMed ID: 24308585
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
9. Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein.
Speake C; Pichugin A; Sahu T; Malkov V; Morrison R; Pei Y; Juompan L; Milman N; Zarling S; Anderson C; Wong-Madden S; Wendler J; Ishizuka A; MacMillen ZW; Garcia V; Kappe SH; Krzych U; Duffy PE
PLoS One; 2016; 11(7):e0159449. PubMed ID: 27434123
[TBL] [Abstract][Full Text] [Related]
10. The GMZ2 malaria vaccine: from concept to efficacy in humans.
Theisen M; Adu B; Mordmüller B; Singh S
Expert Rev Vaccines; 2017 Sep; 16(9):907-917. PubMed ID: 28699823
[TBL] [Abstract][Full Text] [Related]
11. Large screen approaches to identify novel malaria vaccine candidates.
Davies DH; Duffy P; Bodmer JL; Felgner PL; Doolan DL
Vaccine; 2015 Dec; 33(52):7496-505. PubMed ID: 26428458
[TBL] [Abstract][Full Text] [Related]
12. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J
Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604
[TBL] [Abstract][Full Text] [Related]
13. Vaccinating with the genome: a Sisyphean task?
Coppel RL
Trends Parasitol; 2009 May; 25(5):205-12. PubMed ID: 19359219
[TBL] [Abstract][Full Text] [Related]
14. A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.
Radin K; Clement F; Jongert E; Sterckx YG; Ockenhouse C; Regules J; Lemiale F; Leroux-Roels G
Malar J; 2016 Nov; 15(1):543. PubMed ID: 27825382
[TBL] [Abstract][Full Text] [Related]
15. Designing malaria vaccines to circumvent antigen variability.
Ouattara A; Barry AE; Dutta S; Remarque EJ; Beeson JG; Plowe CV
Vaccine; 2015 Dec; 33(52):7506-12. PubMed ID: 26475447
[TBL] [Abstract][Full Text] [Related]
16. The use of transgenic parasites in malaria vaccine research.
Othman AS; Marin-Mogollon C; Salman AM; Franke-Fayard BM; Janse CJ; Khan SM
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525963
[TBL] [Abstract][Full Text] [Related]
17. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
[TBL] [Abstract][Full Text] [Related]
18. Functional Antibodies and Protection against Blood-stage Malaria.
Teo A; Feng G; Brown GV; Beeson JG; Rogerson SJ
Trends Parasitol; 2016 Nov; 32(11):887-898. PubMed ID: 27546781
[TBL] [Abstract][Full Text] [Related]
19. The future for blood-stage vaccines against malaria.
Richards JS; Beeson JG
Immunol Cell Biol; 2009 Jul; 87(5):377-90. PubMed ID: 19417768
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
